BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36476896)

  • 21. Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.
    Golubovskaya V; Zhou H; Li F; Valentine M; Sun J; Berahovich R; Xu S; Quintanilla M; Ma MC; Sienkiewicz J; Huang Y; Wu L
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33652767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].
    Liu Y; Liu Y; Tang KJ; Chen ZQ; Mou JL; Xu YX; Xing HY; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):279-286. PubMed ID: 35680625
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
    Kamiya T; Wong D; Png YT; Campana D
    Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells
    Tian C; Huang P; He Y; Wang L; Peng Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jul; 42(7):1062-1068. PubMed ID: 35869771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells].
    Chen Y; Chen RJ; Huang XC; Tang GX; Kuai XW; Zhang MJ; Zhang DW; Tang Q; Zhu J; Feng ZQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Dec; 53(12):925-930. PubMed ID: 30585005
    [No Abstract]   [Full Text] [Related]  

  • 29. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival
    Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y
    Front Immunol; 2021; 12():724211. PubMed ID: 34675920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.
    Zhao J; Lin L; Luo Y; Cai Q; Jiang X; Liao C; Wei H
    Bioengineered; 2021 Dec; 12(1):3674-3683. PubMed ID: 34261411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 34. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells].
    Zhu HB; Deng Q; Zhang R; Jiang YY; Meng JX; Zhao MF; Li YM; Cui R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):584-588. PubMed ID: 30122019
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
    Yuti P; Wutti-In Y; Sawasdee N; Kongkhla K; Phanthaphol N; Choomee K; Chieochansin T; Panya A; Junking M; Yenchitsomanus PT; Sujjitjoon J
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109442. PubMed ID: 36435066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.